lurasidone (Latuda)

the boxed warning, part one: deaths among older people with dementia-related psychosis

the first part of the boxed warning says that elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death, and that lurasidone is not approved for them [label, boxed warning and 5.1]. the number behind it is a pooled analysis of 17 placebo-controlled trials, mostly of atypical antipsychotics and mostly about 10 weeks long: the death rate was about 4.5% on drug against about 2.6% on placebo, 1.6 to 1.7 times higher. most of the deaths were cardiovascular, such as heart failure or sudden death, or infectious, such as pneumonia [label 5.1; fda-dementia].

it is a class warning written from trials of several antipsychotics; lurasidone was not on the market when those trials ran, and the label does not claim a lurasidone-specific number. a related warning notes that in trials of risperidone, aripiprazole and olanzapine in elderly people with dementia there were more strokes and transient ischaemic attacks, including fatal ones, than on placebo [label 5.3]. the geriatric section adds that the trials did not include enough people over 65 to say whether they respond differently, and that whether the dose should change with age alone is unknown [label 8.5].

the boxed warning, part two: suicidal thoughts and behaviors, by age

the second part is the antidepressant class warning, which lurasidone carries because it is approved for bipolar depression. it says antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents and young adults in short-term studies, and that everyone treated should be watched closely for worsening, especially in the first months and after a dose change [label, boxed warning and 5.2]. the label states the difference against placebo per 1,000 people treated: under 18, 14 additional people with suicidal thoughts or behaviors; 18 to 24, 5 additional; 25 to 64, 1 fewer; 65 and older, 6 fewer [label 5.2, table 2]. the pooled trials covered about 77,000 adults and more than 4,400 children on antidepressants generally, not lurasidone. no suicides occurred in the pediatric trials; the adult trials had too few to conclude anything about suicide itself [label 5.2].

so the warning has an age boundary that is printed in the label and rarely repeated: above age 24 the pooled trials did not show an increase, and above 65 the number runs the other way [label 5.2; age-ceiling]. the label says the risk beyond four months is unknown, and that prescribers should consider changing the regimen, including possibly stopping, in anyone whose depression is persistently worse or who develops suicidal thoughts [label 5.2]. that is an instruction to prescribers about watching, not an instruction to patients about stopping.

the food rule, and the drugs that change the dose

lurasidone should be taken with food of at least 350 calories. with food, the total amount absorbed roughly doubles and the peak level roughly triples, and every trial behind the approval gave it with food [label 2.3]. a dose taken on an empty stomach is therefore a smaller dose than the one that was tested. the label does not say what a 350-calorie meal is; a prescriber or pharmacist can.

the drug is cleared by the liver enzyme cyp3a4, and the label makes two groups of medicines contraindications rather than cautions. strong inhibitors (it names ketoconazole, clarithromycin, ritonavir, voriconazole and mibefradil) raise lurasidone levels and must not be taken with it; strong inducers (rifampin, st john’s wort, phenytoin, carbamazepine) lower them and must not be taken with it either [label 4; 7.1, table 34]. with a moderate inhibitor such as diltiazem, erythromycin, fluconazole or verapamil the label halves the dose, to a 20 mg start and an 80 mg ceiling; with a moderate inducer taken for a week or more it says the dose may need to go up [label 2.6]. grapefruit and grapefruit juice should be avoided, because they disable the same enzyme in the gut wall [label 2.6]; a review of grapefruit interactions lists lurasidone among the affected drugs and notes the effect lasts about a day after the fruit [grapefruit]. lithium and valproate do not change the dose [label 7.2]. the dose is also capped at 80 mg in moderate or severe kidney impairment and at 80 or 40 mg in moderate or severe liver impairment [label 2.4, 2.5].

the metabolic warning, with the label’s tables

warning 5.6 is the class warning that atypical antipsychotics cause hyperglycemia and diabetes, undesirable lipid changes and weight gain, that each drug has its own profile, and that fasting glucose should be tested at the start and periodically in anyone with diabetes risk factors, with regular weight monitoring [label 5.6]. lurasidone’s own tables are unusual in the class for how small the numbers are. they stop at 6 weeks for the controlled data; the open-label extensions run to a year.

• weight, adults with schizophrenia [5.6, table 9]: mean change +0.43 kg on lurasidone against -0.02 kg on placebo over 6 weeks; 4.8% gained 7% or more of body weight against 3.3%. in the same trials the active comparators gained more: +4.15 kg on olanzapine and +2.09 kg on quetiapine extended-release [5.6; 14.1]. in the open-label extensions, mean weight was 0.69 kg below baseline at 24 weeks and 0.73 kg below at 52 weeks.
• weight, bipolar depression [5.6, tables 11 to 13]: +0.29 kg against -0.04 kg as monotherapy (2.4% against 0.7% gaining 7% or more); +0.11 kg against +0.16 kg as an add-on to lithium or valproate (3.1% against 0.3%); in children aged 10 to 17, +0.7 kg against +0.5 kg (4.0% against 5.3%).
• weight, children and adolescents over two years [5.6; 8.4]: in the open-label study that followed the three pediatric trials, 378 of 701 stayed on lurasidone for 104 weeks and gained a mean 5.85 kg. adjusted for normal growth, the change in weight z-score was -0.06 standard deviations and in body-mass index -0.13, which the label calls minimal deviation from the normal curve. mean height gain was 4.94 cm, a z-score change of +0.05.
• blood sugar, adults with schizophrenia [5.6, table 3]: mean fasting glucose change ranged from -0.6 to +2.6 mg/dl across doses against -0.0 on placebo. the share crossing 126 mg/dl was 8.3% on placebo and, by dose, 11.7% (20 mg), 12.7% (40 mg), 6.8% (80 mg), 10.0% (120 mg) and 5.6% (160 mg), with no dose pattern. at 52 weeks of open-label treatment, the mean change was +2.3 mg/dl.
• blood sugar, bipolar depression and children [5.6, tables 4 and 5; 8.4]: +1.8 mg/dl on the lower dose range and -0.8 on the higher against +1.8 on placebo as monotherapy; -0.9 against +1.2 as an add-on. in the 104-week pediatric study, 7% of children with a normal fasting glucose at the start had shifted to high at the end.
• lipids, adults with schizophrenia [5.6, table 6]: total cholesterol fell on every arm including placebo (-5.8 mg/dl on placebo; -3.8 to -12.3 on lurasidone), and so did triglycerides (-13.4 on placebo; -3.1 to -29.1 on lurasidone). the share crossing 240 mg/dl total cholesterol was 5.3% on placebo and 3.8% to 13.8% by dose, the high figure from the 58-person 20 mg arm.
• lipids, children over two years [5.6; 8.4]: in the 104-week open-label study, 12% of children with normal total cholesterol at the start shifted to high, 3% for ldl, 12% for triglycerides, and 27% shifted from normal to low hdl.

movement side effects and restlessness: where lurasidone’s numbers run high

what the metabolic tables give back, the movement tables take. in the 6-week adult schizophrenia trials, any extrapyramidal event was reported by 21% at 40 mg, 23% at 80 mg, 39% at 120 mg and 20% at 160 mg against 9% on placebo [label 6.1, table 24]. akathisia, an inner restlessness with an urge to move that people often find the hardest side effect to live with, was 13% overall against 3%, and 22% at 120 mg [label 6.1, tables 19 and 24]. parkinsonism (stiffness, slowness, tremor) was 9% to 17% against 5%, and dystonia (muscle spasms, often of the neck, jaw or eyes) 4% to 7% against under 1% [label 6.1, table 24]. in adult bipolar depression the pattern repeats at lower rates: any extrapyramidal event 12% on 20 to 60 mg and 20% on 80 to 120 mg against 5% as monotherapy, and 24% against 13% as an add-on [label 6.1, tables 26 and 27]. in adolescents with schizophrenia, 14% against 5% [label 6.1, table 25]; in children with bipolar depression, 6% against 5% [label 6.1, table 28].

tardive dyskinesia [5.5] is the separate, potentially irreversible movement disorder that can follow long antipsychotic treatment. the label says it is impossible to predict who will develop it, that whether antipsychotics differ in their potential to cause it is unknown, that the risk rises with duration and cumulative dose, and that chronic treatment should be reserved for chronic illness with no equally effective, less harmful alternative, at the smallest dose and shortest duration that works, with the need reassessed periodically [label 5.5]. a meta-analysis of 41 studies in 11,493 people put the prevalence at 20.7% on the newer antipsychotics as a class against 30.0% on the older ones, and 7.2% in people who had never taken an older drug; it did not report lurasidone separately [carbon-2017]. neuroleptic malignant syndrome [5.4], a rare and potentially fatal reaction with high fever, rigid muscles, confusion and unstable pulse or blood pressure, has been reported with lurasidone; the label says stop at once and treat in hospital.

the other warnings, in plain words

the warnings section runs from 5.1 to 5.16; the prolactin warning was revised in january 2025 [label, recent major changes]. beyond the boxed warnings, the metabolic one and the movement disorders:

• prolactin [5.7, revised january 2025]: lurasidone raises prolactin, which can suppress reproductive hormones and cause milk production, missed periods, breast enlargement in men and impotence, and over years lower bone density. in the adult schizophrenia trials the median change was +0.4 ng/ml against -1.9 on placebo, with a dose pattern: at 120 and 160 mg the median rise in women was 6.7 and 7.1 ng/ml [table 14]. a rise to five times the upper limit of normal occurred in 2.8% against 1.0%, and in 5.7% of women against 2.0% [5.7]. in the 104-week pediatric study, 2% had a markedly high level at some point; among boys there were no reports of gynecomastia or galactorrhea [5.7].
• low white cells [5.8]: leukopenia and neutropenia have been reported with antipsychotics, and fatal agranulocytosis with other drugs in the class. anyone with a low white count or a history of drug-induced neutropenia needs frequent blood counts in the first months.
• low blood pressure, fainting and falls [5.9, 5.10]: orthostatic hypotension was reported as an adverse event in 0.3% against 0.1%, and syncope in 0.1% against 0%; measured by vital signs it ran 0.8% to 2.1% by dose against 0.7%. the label asks for a fall-risk assessment in anyone whose other conditions or medicines add to drowsiness or unsteadiness.
• seizures [5.11]: 0.1% in both the lurasidone and placebo groups in the schizophrenia trials (2 of 1,508 against 1 of 708); none in the bipolar depression trials.
• drowsiness and impaired thinking [5.12]: somnolence in 17.0% against 7.1% in the adult schizophrenia trials, highest at 120 mg (26.5%) and lowest at 160 mg (8.3%); 7.3% to 13.8% against 6.5% in bipolar depression monotherapy; 11.4% against 5.1% as an add-on; 14.5% against 7.1% in adolescents; 11.4% against 5.8% in children with bipolar depression. the label says not to drive or operate machinery until the effect is known.
• mania [5.14]: fewer than 1% of people in both the lurasidone and placebo groups of the bipolar depression trials developed a manic or hypomanic episode.
• heat [5.13], swallowing [5.15], parkinson’s disease and lewy body dementia [5.16]: antipsychotics can impair the body’s cooling and have been linked to aspiration pneumonia; people with parkinson’s disease or dementia with lewy bodies are reported to be unusually sensitive to them, with confusion, falls and features resembling neuroleptic malignant syndrome.
• kidney blood tests [6.1, tables 29 to 33]: a shift in serum creatinine from normal to high occurred in 5% at 120 mg and 7% at 160 mg against 2% on placebo in adults with schizophrenia, in 7.2% against 2.9% in adolescents, and in 6.7% against 4.5% in children with bipolar depression. the label reports this as a laboratory finding and draws no conclusion from it.
• allergy [4; 6.2]: angioedema has been observed, and hypersensitivity reactions (hives, throat and tongue swelling, breathlessness, rash) and low sodium have been reported since marketing; because they are voluntary reports, no rate can be given.
• pregnancy [8.1]: babies exposed to any antipsychotic in the third trimester are at risk of movement and withdrawal symptoms after birth, from agitation and tremor to feeding and breathing problems; some recovered within hours or days, others needed prolonged hospital care. there are no studies of lurasidone in pregnant women, and the label says the available data cannot inform a risk of birth defects or miscarriage. a pregnancy registry exists.

what the approval trials measured, and for how long

schizophrenia in adults rests on five 6-week placebo-controlled trials of 145, 180, 473, 489 and 482 people, mean age 38. not every dose worked in every trial: in the 489-person trial only the 80 mg dose beat placebo, and 40 mg and 120 mg did not [label 14.1, table 35]. two trials carried an active comparator to show the trial could detect an effect, and in both the comparator scored higher than lurasidone on the primary scale: olanzapine 15 mg beat placebo by 12.6 points on the positive and negative syndrome scale where lurasidone 40 and 120 mg beat it by 9.7 and 7.5, and quetiapine extended-release 600 mg beat placebo by 17.5 points where lurasidone 80 and 160 mg beat it by 11.9 and 16.2 [label 14.1, table 35]. the label says these arms were "included for assay sensitivity", not to compare the drugs, and the trials were not designed to rank them. a 6-week trial in 326 adolescents found 40 and 80 mg both beat placebo by about 8 points, and that 80 mg gave no additional benefit over 40 [label 14.1, table 36].

bipolar depression rests on one 6-week monotherapy trial of 485 adults, in which both dose ranges beat placebo by 4.6 points on the montgomery-asberg scale and the higher range "did not provide additional efficacy"; one 6-week add-on trial of 340 adults, 3.6 points; and one 6-week trial of 343 children aged 10 to 17, 5.7 points on the children’s depression rating scale, with most children ending on 20 or 40 mg [label 14.2, tables 37 and 38]. a 6-week trial of 149 children with irritability associated with autism did not meet its primary endpoint, so there is no autism indication; vomiting ran 27% at 60 mg against 4% on placebo in that trial [label 8.4].

the arithmetic that matters: every controlled trial behind every indication was 6 weeks long. the label states it directly: "the effectiveness of latuda for longer-term use, that is, for more than 6 weeks, has not been established in controlled studies", and the prescriber who continues it "should periodically re-evaluate the long-term usefulness of the drug for the individual patient" [label 2.3]. the safety database adds what the efficacy trials do not: 1,106 adults were followed for at least 24 weeks and 371 for at least 52 [label 6.1], and the longer-term weight, glucose, lipid and prolactin figures above come from those uncontrolled extensions.

side effects, with the label’s numbers

in the 6-week adult schizophrenia trials (1,508 on lurasidone against 708 on placebo), the reactions at 5% or more and at least twice placebo were somnolence, akathisia, extrapyramidal symptoms and nausea [label 6.1]. the table: somnolence 17% against 7%, extrapyramidal disorder 14% against 6%, akathisia 13% against 3%, nausea 10% against 5%, insomnia 10% against 8%, vomiting 8% against 6%, dyspepsia 6% against 5%, agitation 5% against 4%, anxiety 5% against 4%, dizziness 4% against 2%, back pain 3% against 2% [label 6.1, table 19]. dropouts for side effects were 9.5% against 9.3%, and no single reaction caused dropouts at twice the placebo rate [label 6.1].

in adult bipolar depression monotherapy (331 against 168): nausea 14% against 8%, somnolence 11% against 7%, akathisia 9% against 2%, extrapyramidal symptoms 7% against 2%, dry mouth 5% against 4%, anxiety 4% against 1% [label 6.1, table 20]; at the higher dose range nausea was 17% and somnolence 14%. as an add-on (360 against 334): nausea 14% against 10%, extrapyramidal symptoms 14% against 9%, somnolence 11% against 5%, akathisia 11% against 5%, restlessness 4% against under 1%, weight increased 3% against under 1% [label 6.1, table 21].

in adolescents with schizophrenia (214 against 112): somnolence 15% against 7%, nausea 14% against 3%, akathisia 9% against 2%, vomiting 8% against 2%, dizziness 5% against 1% [label 6.1, table 22]. in children with bipolar depression (175 against 172): nausea 16% against 6%, somnolence 11% against 6%, weight increased 7% against 2%, insomnia 5% against 2% [label 6.1, table 23]. one child in the two-year study, a 10-year-old boy, had a prolonged painful erection that led to stopping, an event not reported in adults [label 8.4]. in overdose, the only premarketing case was 560 mg, and the patient recovered without lasting harm [label 10.1].

what the research says, in both directions

in favour. in a network meta-analysis of 402 randomised trials covering 53,463 adults with schizophrenia, all 32 antipsychotics reduced symptoms more than placebo, and the drugs differed more in side effects than in effectiveness [huhn-2019]. on two of those side effects lurasidone sits at the favourable end: its qtc change against placebo, -2.21 milliseconds, was the smallest of the 32, and the abstract’s weight-gain range ran from -0.16 kg for ziprasidone to 3.21 kg for zotepine [huhn-2019, abstract]. a second network meta-analysis of 100 trials in 25,952 people ranked 18 antipsychotics on metabolic effects and named lurasidone, with aripiprazole, brexpiprazole, cariprazine and ziprasidone, as having the most benign profile; its glucose change against placebo, -0.29 mmol/l, was the lowest of the 18, where clozapine’s was +1.05 and olanzapine had the largest body-mass index and ldl rises [pillinger-2020; pillinger-2020, abstract]. that is the research behind the label’s small weight and glucose tables.

against, or smaller than it sounds. the same network meta-analysis found that efficacy differences between antipsychotics were "gradual rather than discrete" and that confidence in the evidence was "often low or very low" [huhn-2019, abstract]; lurasidone’s own approval trials include one in which two of three doses failed and two in which the comparator outscored it [label 14.1]. the metabolic advantage is bought with movement side effects: akathisia at 13% against 3% and any extrapyramidal event at 21% to 39% by dose are among the highest rates in this site’s explainers, where quetiapine’s fixed-dose schizophrenia trial showed none above placebo [label 6.1, table 24; quetiapine-explainer]. tardive dyskinesia remains at about one in five on the newer antipsychotics as a class [carbon-2017]. and every efficacy trial stopped at 6 weeks [label 2.3].

how long to stay on an antipsychotic, in both directions. none of this is lurasidone-specific; it is the class question the label’s 6-week trials cannot answer. a finnish register study of 8,719 people after a first schizophrenia admission found the lowest risk of rehospitalisation or death in those who stayed on an antipsychotic continuously, with the risk rising the longer treatment had lasted before it stopped, and death 174% to 214% higher among non-users and early stoppers; the people who stop are not a random sample [tiihonen-2018]. a dutch randomised trial of 128 people whose first episode had been in remission for six months found, seven years on, twice the recovery rate (40.4% against 17.6%) in those assigned to guided dose reduction rather than maintenance, with more early relapses along the way; it was small, open-label, and its authors asked for more studies before practice changes [wunderink-2013]. both belong in the conversation the label asks for when it says the need for continued treatment should be reassessed periodically [label 5.5].

questions people ask

what does the latuda (lurasidone) black box warning mean?

it has two parts, the same two as quetiapine. first, in 17 placebo-controlled trials of antipsychotics in elderly people with dementia-related psychosis, about 4.5% died over roughly ten weeks against about 2.6% on placebo, 1.6 to 1.7 times the rate, mostly from heart or infectious causes; lurasidone is not approved for that group. second, antidepressants increased suicidal thoughts and behavior in people under 25 in short-term trials (14 extra cases per 1,000 under 18, 5 extra at 18 to 24, 1 fewer at 25 to 64, 6 fewer at 65 and over), and lurasidone carries that warning because it is approved for bipolar depression. neither part is an instruction to stop; both describe who should be watched, and for what.

why does latuda have to be taken with food?

because the label says administration with at least 350 calories roughly doubles the amount absorbed and roughly triples the peak level, and every trial behind the approval gave it with food. taken on an empty stomach, the same tablet delivers a smaller dose than the one that was tested. the label does not define the meal beyond the calorie figure; a pharmacist can.

does latuda cause weight gain?

less than most antipsychotics, on the label’s own numbers. in the 6-week adult schizophrenia trials mean weight change was +0.43 kg against -0.02 kg on placebo, and 4.8% gained 7% or more of body weight against 3.3%; in the same trials olanzapine gained 4.15 kg and quetiapine extended-release 2.09 kg. in the open-label extensions, mean weight at one year was slightly below baseline. a network meta-analysis of 18 antipsychotics placed lurasidone among the five with the most benign metabolic profile. children in the two-year open-label study gained a mean 5.85 kg, which the label calls minimal deviation from normal growth once adjusted for age.

what are the most common latuda side effects?

in the adult schizophrenia trials: somnolence 17% vs 7% on placebo, extrapyramidal symptoms 14% vs 6%, akathisia (inner restlessness) 13% vs 3%, nausea 10% vs 5%. akathisia reached 22% at 120 mg. in bipolar depression: nausea 14% vs 8%, somnolence 11% vs 7%, akathisia 9% vs 2%. in children with bipolar depression: nausea 16% vs 6%, weight increase 7% vs 2%. movement side effects are where lurasidone’s numbers run higher than quetiapine’s; weight and blood sugar are where they run lower.

latuda vs seroquel: what does the public record show?

two drugs with the same two-part boxed warning and opposite side-effect profiles. the lurasidone label shows +0.43 kg of weight gain over 6 weeks and akathisia in 13% of people; the quetiapine label shows 23% of people gaining 7% or more of their weight in the same period and no movement side effects above placebo in its fixed-dose schizophrenia trial. in the one approval trial that included both, quetiapine extended-release 600 mg beat placebo by more points than lurasidone 80 or 160 mg, but the label says that arm was there to check the trial worked, not to compare the drugs. lurasidone must be taken with food; quetiapine is far more sedating (somnolence 57% in its bipolar depression trials against 11% for lurasidone). the quetiapine explainer and the side-by-side comparison page are linked in the sources. which fits a given person is a prescriber conversation.

is latuda (lurasidone) a controlled substance or addictive?

it is not a controlled substance. the label says lurasidone "has not been systematically studied in humans for its potential for abuse or physical dependence", that the trials showed no drug-seeking behaviour, and that this is not enough to predict misuse once marketed, so people with a history of drug misuse should be watched for tolerance, dose escalation and drug-seeking.

how long do people take latuda for, and how long was it tested?

every controlled trial behind every indication lasted 6 weeks, and the label states that effectiveness beyond 6 weeks "has not been established in controlled studies", asking prescribers who continue it to re-evaluate its usefulness periodically. the safety database followed 1,106 adults for at least 24 weeks and 371 for at least 52. how long to stay on an antipsychotic is a class question: a finnish register study found the lowest rehospitalisation and death rates in people who stayed on treatment, and a small dutch randomised trial found twice the recovery rate seven years after guided dose reduction in people already in remission. a plan for reducing or stopping belongs with a prescriber.

sources for this section

the library rows link to our one-page summary of each study, with the original paper, its funding and our evidence grade on that page.

1. latuda (lurasidone hydrochloride) tablets prescribing information, fda label on dailymed (set id afad3051-9df2-4c54-9684-e8262a133af8, version 37, effective january 31, 2025; sumitomo pharma america): boxed warning; sections 1, 2.2 to 2.6, 4, 5.1 to 5.16 with tables 2 to 18, 6.1 tables 19 to 33, 6.2, 7.1 table 34, 7.2, 8.1, 8.4, 8.5, 9.1, 9.2, 10.1, 14.1 and 14.2 with tables 35 to 38, recent major changes
2. drugs@fda, nda 200603 (latuda), approved october 28, 2010
3. ahrq medical expenditure panel survey, prescribed medicines public-use files 2014 (hc-168a) to 2024 (hc-254a): lurasidone has no reportable year (fewer than 60 respondents in 2014 to 2021; name masked in the public file for 2022 to 2024); method on the usage section of this page
4. the antipsychotic dementia-mortality warning as a library row: the 17-trial pooled analysis, the 2005 and 2008 fda actions, and the questions it raises (library row)
5. the antidepressant suicidality warning’s age ceiling, from the labels themselves, as a library row (library row)
6. huhn m, et al. comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. lancet 2019 (library row written up for aripiprazole; the lurasidone qtc figure and the quoted conclusions are from the abstract, pubmed 31303314) (library row)
7. pillinger t, et al. comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. lancet psychiatry 2020 (library row written up for aripiprazole; the lurasidone glucose figure is from the abstract, pubmed 31860457; uk medical research council and wellcome trust funding) (library row)
8. carbon m, hsieh ch, kane jm, correll cu. tardive dyskinesia prevalence in the period of second-generation antipsychotic use: a meta-analysis. journal of clinical psychiatry 2017 (library row)
9. tiihonen j, tanskanen a, taipale h. 20-year nationwide follow-up study on discontinuation of antipsychotic treatment in first-episode schizophrenia. american journal of psychiatry 2018 (register study; the row records the selection caution) (library row)
10. wunderink l, et al. recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy. jama psychiatry 2013 (randomised, open-label, 128 people) (library row)
11. bailey dg, dresser g, arnold jm. grapefruit-medication interactions: forbidden fruit or avoidable consequences? cmaj 2013 (narrative review; lurasidone is in its tables) (library row)
12. what the quetiapine (seroquel) warnings mean, the companion explainer on this site, written from the quetiapine label the same way
13. latuda vs seroquel: the public record side by side (usage, payers, label warnings, approval history), a separate page on this site

Extrapyramidal symptoms and akathisia on the lurasidone label

The lurasidone FDA label names extrapyramidal symptoms and akathisia in its Adverse Reactions section, in the list below.

Most-reported reactions

• Off label use2,078
• Drug ineffective1,864
• Anxiety1,236
• Feeling abnormal1,170
• Depression1,142
• Weight increased1,095
• Somnolence1,076
• Nausea1,051
• Insomnia1,014
• Suicidal ideation979